/PRNewswire/ As the focus on the COVID-19 pandemic shifts to raising the number of vaccinated people around the world, U.S. researchers, funded by the NIH,.
Share this article
Share this article
BOSTON, Feb. 24, 2021 /PRNewswire/ Researchers at two major medical centers in Israel, Rambam Medical Health Care Campus and Ziv Medical Center, have initiated a Phase 2 clinical trial of a promising new treatment for COVID-19.
These trials are testing TXA27, a compound with an established safety profile. TXA127 has been developed by Boston-based Constant Therapeutics We are examining the use of a drug based on a naturally occurring peptide called Angiotensin (1-7), that prevents cell proliferation and inflammation in the lungs, said Professor Karl Skorecki, Dean of the Azrieli Faculty of Medicine of Bar-Ilan University in the Galilee.